Indian generics slowly moving towards invention model but incentives are scant

In light of the recent headline-making Glivec decision, all eyes are now on the Indian pharmaceutical industry. Amidst all the clamour about whether or not India is anti-patent or if big pharma will look elsewhere to invest, no-one seems to be…

Get unlimited access to all IAM content